230 (PB110) - Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors

Autor:	Fontana, E. 1, Williams, A. 1, Falchook, G. 2, Lakhani, N. 3, Evans, T.R.J. 4, Gondi, V. 5, Iwamoto, F. 6, McKean, M. 7, Symeonides, S. 8, Butowski, N. 9, McLaren, A. 10, Henry, J. 2, Buerki, R. 5, Rotolo, J. 11, Capiaux, G. 11, Michel, R. 11, Kaesshaefer, S. 11, Wiegert, E. 11, Bexon, A. 11
Zdroj:	In European Journal of Cancer October 2022 174 Supplement 1:S82-S83
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect